Special Issue "Pathogenesis and Therapy of Chronic Kidney Disease-Associated Itch (Uremic Pruritus)"
Deadline for manuscript submissions: 31 January 2022.
Interests: chronic kidney disease; uremic toxins; chronic kidney disease-associated itch; psychosocial; health-related quality of life
Interests: systemic itch; uremic pruritus; itch in dermatoses; skin and psyche
Special Issues and Collections in MDPI journals
Chronic kidney disease (CKD) is a growing problem worldwide, with prevalence of advanced stages (three to five stages) in about 11% of the general population. CKD is associated with numerous complications, with cutaneous ones being considered common. CKD-associated itch, for years also called uremic pruritus, is defined as chronic itch in patients with CKD with advanced stages of renal damage. The diagnosis includes the exclusion of other possible causes. CKD-associated itch is regarded as one of the most bothersome symptoms in patients requiring dialysis treatment. Its prevalence is currently estimated at 40% among dialysis patients. Although described for the first time in 1932, CKD-associated itch is still an unsolved and important clinical challenge. As the pathogenesis is not completely clear, there is no one “gold” treatment available and registered. The pathogenesis of this type of itch is multifactorial, with several factors contributing to the development and/or exacerbation of this sensation. Recently, several studies have been conducted to understand the processes leading to chronic itch in uremic patients in more depth. This resulted in new hypotheses and new treatment targets (within the neural and immune system) for CKD-associated itch. Several new agents specifically aiming to relive CKD-associated itch (e.g., difelikefalin, nalbuphine) are under development. The aim of this Special Issue is to offer a platform, both for clinicians and basic researchers, to present and discuss novel issues in the pathogenesis and treatment of CKD-associated itch. We do hope that all published papers will significantly contribute to a better understanding of CKD-associated itch and will be of benefit for suffering patients in the future.
Prof. Dr. Katarzyna Kilis-Pstrusinska
Prof. Dr. Jacek Szepietowski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Chronic itch
- Chronic kidney disease-associated itch
- Treatment options
- Anti-interleukin agents.